Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-5 (2021)
Introduction We present seven cases of infectious keratitis after corneal crosslinking (CXL) to attenuate keratoconus progression. Methods Of 524 consecutive patients who underwent CXL, 7 cases (4 males and 3 females; 21.5 ± 7.1 years) developed pos
Autor:
Hamed Radmehr, Alireza Dehghani, Farzan Kianersi, Afsaneh Naderi Beni, Pegah Noorshargh, Mohammadreza Akhlaghi
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-8 (2021)
Background One of the major side effects of Hydroxychloroquine (HCQ) is retinopathy. The aim of this study was to evaluate the Optical coherence tomography angiography (OCTA) parameters in a group of patients who have Hydroxychloroquine-induced retin
Autor:
Abdoulaye Napo, Serge Resnikoff, Abba Kaka Hadja Yakoura, Michel Gouda, Fatoumata Sylla, Robert C. Della Rocca, Seydou Bakayoko, LI Traoré, Rodrigue Romulad Elien, Nouhoum Guirou
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-4 (2021)
BMC Ophthalmology, Vol 21, Iss 1, Pp 1-4 (2021)
Background Ocular damage, including damage to the conjunctiva, lacrimal gland, eyelids, and orbit, caused by Schistosoma haematobium is sporadic. We report a clinical case of orbital migration of schistosome eggs. Case presentation A 14-year-old boy
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
Background Numerous cytokines have been proven to participate in the pathogenesis of neovascular age-related macular degeneration (nAMD). The present study aimed to investigate the aqueous humor cytokine expression profile in nAMD patients before and
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-8 (2020)
Background The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab and bevacizumab in diabetic macular edema (DME). Post -hoc analyses showed that after a 12-week
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-9 (2020)
Background It is not clear whether macular laser combined with anti-vascular endothelial growth factor (VEGF) can reduce the number of anti-VEGF injections in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Our
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-7 (2020)
Background The development of ghost cell glaucoma in patients with proliferative diabetic retinopathy (PDR) after intravitreous injection (IV) was rare. Here we reported a series of patients with PDR who received Intravitreous Ranibizumab (IVR) and d
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-5 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-5 (2020)
Background To report a bilateral cystoid macular edema associated with Henoch-Schonleinpurpura. Case presentation A 21-year-old man presented a bilateral, painless, and bilateral blurred vision for 5 weeks with visual acuity (VA) of 6/12 on the right
Autor:
Justus G. Garweg, Boris Gekkiev, Giovanni Staurenghi, Bianca S. Gerendas, Philippe Margaron, Wayne Macfadden, Petr Kolar, Cornelia Dunger-Baldauf
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-11 (2020)
Background To evaluate the efficacy and safety of two individualized ranibizumab retreatment schemes in neovascular age-related macular degeneration. Methods Patients (N = 671) were randomized (1:1) to receive three initial monthly ranibizumab 0.5 mg
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, Vol 19, Iss 1, Pp 1-4 (2019)
BMC Ophthalmology, Vol 19, Iss 1, Pp 1-4 (2019)
Background The relationship between anti-estrogen drugs and macular telangiectasia type 2 (MacTel-2) remains unknown. Here we report a case with anti-estrogen maculopathy resembling MacTel-2 with improved visual function and macular morphology follow